Personalis Gross Profit 2011-2026 | PSNL

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Personalis

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	22.1 M	11.8 M	-2.34 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.1 M	-2.34 M	10.5 M

Quarterly Gross Profit Personalis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.56 M	5.63 M	5.9 M	3.98 M	4.83 M	4.48 M	2.4 M	99 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.56 M	99 K	4.24 M

Gross Profit of other stocks in the Diagnostics research industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
Akumin AKU	53.5 M	-	-17.87 %	$ 25.9 M	Canada
Centogene N.V. CNTG	17.2 M	-	-6.23 %	$ 30.6 M	Germany
Chembio Diagnostics CEMI	6.58 M	-	0.22 %	$ 16.8 M	USA
Brainsway Ltd. BWAY	30.6 M	$ 23.6	-2.44 %	$ 99.4 M	Israel
Burning Rock Biotech Limited BNR	364 M	$ 23.7	1.08 %	$ 256 M	China
Biocept BIOC	6.12 M	-	-13.05 %	$ 7.29 M	USA
Co-Diagnostics CODX	2.63 M	$ 2.72	-54.5 %	$ 79.8 M	USA
Accelerate Diagnostics AXDX	842 K	-	-61.36 %	$ 2.46 M	USA
Castle Biosciences CSTL	53 M	$ 39.55	-0.28 %	$ 1.1 B	USA
DermTech DMTK	276 K	-	-11.32 %	$ 2.94 M	USA
DexCom DXCM	2.29 B	$ 70.09	-1.25 %	$ 27.1 B	USA
BioNano Genomics BNGO	2.77 M	$ 1.57	-1.26 %	$ 2 M	USA
Oxford Immunotec Global PLC OXFD	54.4 M	-	-	$ 562 M	Britain
Guardant Health GH	144 M	$ 108.18	0.57 %	$ 13.3 B	USA
Global Cord Blood Corporation CO	1.06 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	83.3 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	-251 K	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	281 M	-	0.12 %	$ 80.1 M	China
Illumina ILMN	2.86 B	$ 146.79	0.86 %	$ 23.3 B	USA
PRA Health Sciences, Inc. PRAH	869 M	-	-	$ 10.7 B	USA
CareDx, Inc CDNA	81.6 M	$ 20.22	-1.7 %	$ 1.09 B	USA
IQVIA Holdings IQV	3.79 B	$ 241.66	0.27 %	$ 43.8 B	USA
Danaher Corporation DHR	14.2 B	$ 234.99	-1.7 %	$ 172 B	USA
DarioHealth Corp. DRIO	5.98 M	$ 12.27	5.14 %	$ 348 M	Israel
Anixa Biosciences ANIX	83.8 K	$ 3.26	3.01 %	$ 106 K	USA
Enzo Biochem ENZ	23.2 M	-	-8.98 %	$ 14.8 K	USA
Lantheus Holdings LNTH	988 M	$ 66.09	-2.06 %	$ 4.57 B	USA
Exact Sciences Corporation EXAS	493 M	$ 102.3	0.06 %	$ 19 B	USA
Medpace Holdings MEDP	246 M	$ 608.79	1.6 %	$ 18.8 B	USA
Fulgent Genetics FLGT	107 M	$ 28.41	0.89 %	$ 859 M	USA
Aspira Women's Health AWH	4.32 M	-	-6.19 %	$ 10.5 M	USA
Motus GI Holdings MOTS	-398 K	-	-34.28 %	$ 263 K	Israel
Myriad Genetics MYGN	585 M	$ 6.2	-5.63 %	$ 562 M	USA
National Research Corporation NRC	81.5 M	$ 20.86	2.1 %	$ 512 M	USA
Natera NTRA	127 M	$ 239.28	1.63 %	$ 23.5 B	USA
OPKO Health OPK	219 M	$ 1.34	0.38 %	$ 930 M	USA
Pacific Biosciences of California PACB	52.8 M	$ 2.13	5.72 %	$ 540 M	USA
Charles River Laboratories International CRL	958 M	$ 219.6	0.29 %	$ 11.3 B	USA
Heska Corporation HSKA	111 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	4.56 M	-	-20.0 %	$ 1.06 M	USA
Mettler-Toledo International MTD	2.33 B	$ 1 476.52	-1.07 %	$ 31.3 B	Schweiz
ENDRA Life Sciences NDRA	6.17 K	$ 4.51	-	$ 2.42 M	USA
Invitae Corporation NVTA	98.7 M	-	-	$ 21.2 M	USA
Neogen Corporation NEOG	421 M	$ 9.16	-2.19 %	$ 1.99 B	USA
Quest Diagnostics Incorporated DGX	2.69 B	$ 179.97	2.8 %	$ 20 B	USA
Biodesix BDSX	18.5 M	$ 9.72	20.31 %	$ 1.26 B	USA
Organovo Holdings ONVO	1.87 M	-	-2.3 %	$ 19.4 M	USA